DUBLIN, August 9, 2016 /PRNewswire/ --

Research and Markets has announced the addition of the "Dendrimers and Polymer Drug Conjugates Market, 2016 - 2026" report to their offering.

The Dendrimers and Polymer Drug Conjugates Market, 2016-2026 report delivers a comprehensive study on the emergence of nanocarriers as a significant tool for drug delivery, therapeutics and diagnostics. For the purpose of this report, we have primarily focused on the following two types of nanocarriers.

The report assesses key drivers that have governed the evolution of polymer drug conjugates over the past several years and determines the market in a long term (2016-2026). The research, analysis and insights presented in this report include potential sales of the drugs in phase III and phase II of development. To add robustness to our forecast model, we have provided three market scenarios. The conservative, base and optimistic scenarios represent three different tracks of market evolution. In addition, we have provided a detailed discussion on the future trends and the key opportunity areas for dendrimers that are likely to shape the market in the coming years.

Example Highlights

- Nearly 40 polymer drug conjugates are currently in clinical and preclinical stages of development; molecules in phase III and II account for nearly 19% of the pipeline while 26% is captured by molecules in phase I/II and I.

- There are several types of dendrimers being used for both commercial and research purposes in the pharmaceutical domain; the dendrimers most widely used for industry applications include PAMAM, PLL, Priostar®, Astramol®. However, with over 4000 papers published between 2006 and 2016 (as reported in PubMed), dendrimers are being extensively explored by researchers in the non-industry / academic institutes.

- With one commercialized therapeutic product (VivaGel®) and several other marketed dendrimer-based products (SuperFect®, Stratus® CS, PrioFect, Alert Ticket), Starpharma has emerged as a forerunner in the dendrimer market.

- Amongst the different biomedical applications that dendrimers and polymer drug conjugates serve, drug delivery holds a large opportunity. Several big pharma players as AstraZeneca, Eli Lilly, GSK's Stiefel have collaborated with dendrimer technology developers (such as DEP® Technology by Starpharma) to improve the therapeutic efficacy and drug delivery properties of their existing products. Additionally, polymer drug conjugates have expanded their focus to a broad range of diseases exploring different routes of administrations for better drug delivery.

- The polymer drug conjugates market momentum will be driven by the success of current batch of late stage clinical molecules; these primarily include NKTR-181 (by Nektar Therapeutics), NKTR-102 (by Nektar Therapeutics), CRLX101 (by Cerulean Pharma) and Opaxio (by CTI BioPharma).

- Specific molecules such as NKTR-181 and NKTR-102 are anticipated to achieve a block buster status in the near future. With eight molecules (two mentioned above and six others in lower stages of development) in development, Nektar Therapeutics is expected to play an important role in the market's evolution.

Key Topics Covered:

1. Preface

1.1.Scope Of The Report

1.2.Research Methodology

1.3.Chapter Outlines

2. Executive Summary

3. Introduction

3.1.The Concept Of Nanotechnology

3.2.Nanomedicine: A Potential Platform For Therapeutic Applications

3.3.Applications Of Nanomedicine

3.4.Nanocarriers: Important Tools For Nanomedicine

3.5.Nanocarriers And Drug Approvals

4. Market Landscape

4.1.Chapter Overview

4.2.Dendrimers: Product List And Classes

4.3.Polymer Drug Conjugates: Development Pipeline

5. Dendrimers: A Detailed Review

5.1.An Introduction To Dendrimers

5.2.Synthesis Of Dendrimers

5.3.Characterization Of Dendrimers

5.4.Properties Of Dendrimers

5.5.Advantages Of Dendrimers

5.6.Applications Of Dendrimers

5.7.Classification Of Dendrimers

5.8.Types Of Dendrimers

5.9.Commercialized Dendrimers

6. Polymer Drug Conjugates: Drug Profiles

6.1.The Rationale Of Polymer Drug Conjugates

6.2.Designing And Characterization Of Polymer Drug Conjugates

6.3.Most Common Polymers

6.4.Most Common Drugs

6.5.Advantages Of Polymer Drug Conjugates

6.6.Polymer Drug Conjugates In Oncology And Other Diseases

6.7.Polymer Drug Conjugates: Drug Profiles

7. Market Forecast And Opportunity Analysis

7.1.Chapter Overview

7.2.Polymer Drug Conjugates: Future Projections

7.3.Dendrimers: Opportunity Areas

8. Conclusion

8.1.The Evolving Era Of Polymer Therapeutics Offers Significant Promise To The Pharmaceuticals Market

8.2.Amongst All The Applications, Drug Delivery Holds A Large Opportunity

8.3.The Dendrimer Market Is Yet To Unveil Itspotential In The Biomedical Industry

8.4.Polymer Drug Conjugates Are Being Exploited For Numerous Therapeutic Areas

8.5.With Success Of The Already Commercialized Drugs, The Next Generation Of Polymer Drug Conjugates Are Poised To Witness An Accelerated Growth

9. Appendix 1: Tabulated Data

10. Appendix 2: List Of Companies And Organizations

- 3S Bio

- ASCEND Therapeutics

- Abeona Therapeutics

- Abramson Cancer Center

- Access Pharmaceuticals

- Adama

- Ajinomoto Althea

- Allergan

- Alliance for Clinical Trials in Oncology

- Allied Corporation

- Althea Technologies

- Altus Pharmaceuticals

- Amgen

- Ansell Limited

- Arsenal Medical

- Ascendis Pharma

- Aspen Pharmacare

- AstraZeneca

- BIND Sciences

- Baxalta

- Belrose Pharma

- Beth Israel Deaconess Medical Center

- Biogen

- Brown University

- CTI BioPharma

- Cancer Therapeutics

- Carlina Technologies

- Cellular Therapeutics

- Cerulean Pharma

- City of Hope Medical Center

- Clemson University

- Colcom

- Cosmo Pharmaceuticals

- Crealta Pharmaceuticals

- CytImmune

- Dade Behring

- Dana-Farber Cancer Institute

- Dartmouth-Hitchcock Medical Center

- DelSiTech

- Delta-Fly Pharma

- Dendritech Nanotechnologies

- Dow Chemical

- Durect Corporation

- EMD Biosciences

- Edge Therapeutics

- Eli Lilly

- Enzon Pharmaceuticals

- Eunice Kennedy Shriver National Institute of Child Health and Human Development

- Eyetech

- Ferring

- Flamel Technologies

- Genentech

- GlaxoSmithKline

- Gowan

- Gynecologic Oncology Group Foundation

- JenKem Technology

- Landec

- Lipotek

- M.D. Anderson Cancer Center

- MakhteshimAgan

- Massachusetts General Hospital

- Massachusetts Institute of Technology

- Memorial Sloan Kettering Cancer Center

- Merck

- Mersana Therapeutics

- Michigan Nanotechnology Institute for Medicine and Biological Sciences

- Mountain View Pharmaceuticals

- Mylan

- Nanovector

- National Cancer Institute

- National Heart and Lung Institute

- National Institute of Allergy and Infectious Diseases

- National Institute of Mental Health

- National Institute on Drug Abuse

- National Institutes of Health

- National Nanotechnology Initiative

- Nektar Therapeutics

- NeuroNano Pharma

- Novartis

- Nufarm

- Oakwood Laboratories

- Octoplus

- Okamoto Industries

- Ontario Institute for Cancer Research

- PG-TXL

- Peptineo

- Pfizer

- Pharmacia and Upjohn Company

- PolyActiva

- PolyPid

- Polymer Factory

- ProCore Bio Med

- ProLynx

- Qiagen

- Reckitt Benckiser

- Rexahn Pharmaceuticals

- Roche

- Roswell Park Cancer Institute

- SUNY Upstate Medical University

- Sagent Pharmaceuticals

- Sanofi-Aventis

- Santarus

- Savient Pharmaceuticals

- Schering Plough

- Serina Therapeutics

- Shire

- Sigma Aldrich

- Sitka Biopharma

- Sloan-Kettering Institute for Cancer Research

- Sonoran Biosciences

- Stanford Cancer Institute

- Stanford University

- Starpharma

- Stiefel Laboratories

- Sun Pharma

- SyMO-Chem

- Teva Pharmaceutical

- The Methodist Hospital System

- The State University of New York

- UCB Pharma

- UNC Lineberger Comprehensive Cancer Center

- US Army Research Laboratory

- University of Chicago

- University of Colorado Boulder

- University of Glasgow

- University of Illinois

- University of Maryland

- University of Pennsylvania

- University of Southern California

- University of Washington

- Weihai CY

- World Health Organization

- Wyss Institute

- XstalBio

- Yamanouchi Pharmaceutical

- pSivida

For more information visit http://www.researchandmarkets.com/research/2pf68r/dendrimers_and

About Research and Markets

Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Media Contact:

Laura Wood, Senior Manager

press@researchandmarkets.com 

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907

Fax (outside U.S.): +353-1-481-1716

Related Links

http://www.researchandmarkets.com

SOURCE Research and Markets